Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients With Relapsed and/or Refractory Multiple Myeloma: Results From at Least 1-Year Follow-Up in all Patients

被引：0
|
作者：
Frigault, Matthew [1 ]
Rosenblatt, Jacalyn [2 ]
Dhakal, Binod [3 ]
Raje, Noopur [4 ]
Cook, Daniella [1 ]
Gaballa, Mahmoud [5 ]
Emmanuel-Alejandro, Estelle [2 ]
Nissen, Danielle [3 ]
Banerjee, Kamalika [6 ]
Rotte, Anand [6 ]
Heery, Christopher [6 ]
Avigan, David [2 ]
Jakubowiak, Andrzej [7 ]
Bishop, Michael [7 ]
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA
[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[3] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Arcellx Inc, Redwood City, CA USA
[7] Univ Chicago, Chicago, IL 60637 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
MM; multiple myeloma; BCMA; plasma cell; anitocabtagene autoleucel;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MM-364
引用
收藏
页码：S553 / S553
页数：1
相关论文
共 50 条
  • [21] Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma
    Frigault, Matthew J.
    Bishop, Michael R.
    Rosenblatt, Jacalyn
    O'Donnell, Elizabeth K.
    Raje, Noopur
    Cook, Daniella
    Yee, Andrew J.
    Logan, Emma
    Avigan, David E.
    Jakubowiak, Andrzej
    Shaw, Kit
    Daley, Heather
    Nikiforow, Sarah
    Griff, Faith
    Cornwell, Christine
    Shen, Angela
    Heery, Christopher
    Maus, Marcela V.
    BLOOD ADVANCES, 2023, 7 (05) : 768 - 777
  • [22] Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma
    Hussein, MA
    Saleh, M
    Ravandi, F
    Mason, J
    Rifkin, RM
    Ellison, R
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (04) : 470 - 476
  • [23] Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma
    Eric K. Rowinsky
    Agne Paner
    Jesus G. Berdeja
    Claudia Paba-Prada
    Parameswaran Venugopal
    Kimmo Porkka
    Joachim Gullbo
    Stig Linder
    Angelica Loskog
    Paul G. Richardson
    Ola Landgren
    Investigational New Drugs, 2020, 38 : 1448 - 1453
  • [24] Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1
    Bringhen, Sara
    Voorhees, Peter M.
    Plesner, Torben
    Mellqvist, Ulf-Henrik
    Reeves, Brandi
    Sonneveld, Pieter
    Byrne, Catriona
    Nordstrom, Eva
    Harmenberg, Johan
    Obermuller, Jakob
    Richardson, Paul G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (06) : 1105 - 1109
  • [25] Longer-Term Follow-up of Patients Receiving Prophylactic Tocilizumab for the Reduction of Cytokine Release Syndrome (CRS) in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma (RRMM)
    van de Donk, Niels W. C. J.
    Garfall, Alfred L.
    Benboubker, Lotfi
    Uttervall, Katarina
    Groen, Kaz
    Rosinol, Laura
    Matous, Jeffrey V.
    Vishwamitra, Deeksha
    Hodin, Caroline
    Stephenson, Tara
    Qi, Keqin
    Zuppa, Athena
    Chastain, Katherine
    Mateos, Maria-Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S549 - S549
  • [26] Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study
    Sjoerd Hovenga
    Simon M. G. J. Daenen
    Joost T. M. de Wolf
    Gustaaf W. van Imhoff
    Hanneke C. Kluin-Nelemans
    Wim J. Sluiter
    Edo Vellenga
    Annals of Hematology, 2005, 84 : 311 - 316
  • [27] A phase II trial with gemcitabine and paclitaxel for the treatment of refractory and relapsed multiple myeloma patients
    Gazitt, Yair
    Shaughnessy, Paul
    Rothenberg, Mace L.
    ONCOLOGY REPORTS, 2006, 16 (04) : 877 - 884
  • [28] Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study
    Hovenga, S
    Daenen, SMGJ
    de Wolf, JTM
    van Imhoff, GW
    Kluin-Nelemans, HC
    Sluiter, WJ
    Vellenga, E
    ANNALS OF HEMATOLOGY, 2005, 84 (05) : 311 - 316
  • [29] Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma
    Jin, Chunxiang
    Chen, Rongrong
    Fu, Shan
    Zhang, Mingming
    Teng, Yuanyin
    Yang, Tingting
    Song, Fengmei
    Feng, Jingjing
    Hong, Ruimin
    Cui, Jiazhen
    Huang, Simao
    Xu, Huijun
    Zhang, Yanlei
    Wei, Guoqing
    Cai, Zhen
    Kwong, Yok-Lam
    Chan, Thomas Sau Yan
    Chang, Alex H.
    Huang, He
    Hu, Yongxian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (03)
  • [30] Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma
    Suzuki, Kenshi
    Handa, Hiroshi
    Chou, Takaaki
    Ishizawa, Kenichi
    Takubo, Takatoshi
    Kase, Yoichi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 105 (04) : 445 - 452
12345